Loading...

Riociguat for pulmonary arterial hypertension associated with congenital heart disease

OBJECTIVE: The Pulmonary Arterial hyperTENsion sGC-stimulator Trial-1 (PATENT-1) was a randomised, double-blind, placebo-controlled phase III trial evaluating riociguat in patients with pulmonary arterial hypertension (PAH). PATENT-2 was an open-label long-term extension to PATENT-1. Here, we explor...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Heart
Main Authors: Rosenkranz, Stephan, Ghofrani, Hossein-Ardeschir, Beghetti, Maurice, Ivy, Dunbar, Frey, Reiner, Fritsch, Arno, Weimann, Gerrit, Saleh, Soundos, Apitz, Christian
Format: Artigo
Sprog:Inglês
Udgivet: BMJ Publishing Group 2015
Fag:
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4680166/
https://ncbi.nlm.nih.gov/pubmed/26135803
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/heartjnl-2015-307832
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!